Research Progress of Duodenal-Jejunal Bypass Liner in the Treatment of Obesity and Type 2 Diabetes Mellitus

References

• World Health Organization. Obesity and Overweight. World Health Organization; 2021.
   Google Scholar
• International Diabetes Federation (IDF). IDF Diabetes Atlas 2021. International Diabetes Federation (IDF); 2021.
   Google Scholar
• World Health Organization. The Top 10 Causes of Death. World Health Organization; 2020.
   Google Scholar
• Chen G, Zhang GX, Peng BQ, Cheng Z, Du X. Roux-En-Y gastric bypass versus sleeve gastrectomy plus procedures for treatment of morbid obesity: systematic review and meta-analysis. Obes Surg. 2021;31(7):3303–3311. doi:10.1007/s11695-021-05456-0
   Web of Science ®Google Scholar
• Fishman E, Melanson D, Lamport R, Levine A. A novel endoscopic delivery system for placement of a duodenal-jejunal implant for the treatment of obesity and type 2 diabetes. Annu Int Conf IEEE Eng Med Biol Soc. 2008;2008:2501–2503. doi:10.1109/IEMBS.2008.4649708
   Google Scholar
• Rodriguez-Grunert L, Galvao Neto MP, Alamo M, Ramos AC, Baez PB, Tarnoff M. First human experience with endoscopically delivered and retrieved duodenal-jejunal bypass sleeve. Surg Obes Relat Dis. 2008;4(1):55–59. doi:10.1016/j.soard.2007.07.012
   PubMed Web of Science ®Google Scholar
• de Moura EG, Martins BC, Lopes GS, et al. Metabolic improvements in obese type 2 diabetes subjects implanted for 1 year with an endoscopically deployed duodenal-jejunal bypass liner. Diabetes Technol Ther. 2012;14(2):183–189. doi:10.1089/dia.2011.0152
   PubMed Web of Science ®Google Scholar
• de Jonge C, Rensen SS, Verdam FJ, et al. Endoscopic duodenal-jejunal bypass liner rapidly improves type 2 diabetes. Obes Surg. 2013;23(9):1354–1360. doi:10.1007/s11695-013-0921-3
   PubMed Web of Science ®Google Scholar
• Betzel B, Homan J, Aarts EO, et al. Weight reduction and improvement in diabetes by the duodenal-jejunal bypass liner: a 198 patient cohort study. Surg Endosc. 2017;31(7):2881–2891. doi:10.1007/s00464-016-5299-6
   Web of Science ®Google Scholar
• Deutsch L, Ben Haim L, Sofer Y, Gluck N, Santo E, Fishman S. Long-term effects of proximal small bowel exclusion by duodenal-jejunal bypass liner on weight reduction and glycemic control in diabetic patients. Surg Obes Relat Dis. 2018;14(10):1561–1569. doi:10.1016/j.soard.2018.07.022
   Web of Science ®Google Scholar
• Tarnoff M, Rodriguez L, Escalona A, et al. Open label, prospective, randomized controlled trial of an endoscopic duodenal-jejunal bypass sleeve versus low calorie diet for pre-operative weight loss in bariatric surgery. Surg Endosc. 2009;23(3):650–656. doi:10.1007/s00464-008-0125-4
   Web of Science ®Google Scholar
• Gersin KS, Rothstein RI, Rosenthal RJ, et al. Open-label, sham-controlled trial of an endoscopic duodenojejunal bypass liner for preoperative weight loss in bariatric surgery candidates. Gastrointest Endosc. 2010;71(6):976–982. doi:10.1016/j.gie.2009.11.051
   PubMed Web of Science ®Google Scholar
• Schouten R, Rijs CS, Bouvy ND, et al. A multicenter, randomized efficacy study of the EndoBarrier Gastrointestinal Liner for presurgical weight loss prior to bariatric surgery. Ann Surg. 2010;251(2):236–243. doi:10.1097/SLA.0b013e3181bdfbff
   PubMed Web of Science ®Google Scholar
• Koehestanie P, de Jonge C, Berends FJ, Janssen IM, Bouvy ND, Greve JW. The effect of the endoscopic duodenal-jejunal bypass liner on obesity and type 2 diabetes mellitus, a multicenter randomized controlled trial. Ann Surg. 2014;260(6):984–992. doi:10.1097/SLA.0000000000000794
   PubMed Web of Science ®Google Scholar
• Obermayer A, Tripolt NJ, Aziz F, et al. EndoBarrier™ implantation rapidly improves insulin sensitivity in obese individuals with type 2 diabetes mellitus. Biomolecules. 2021;11(4):574. doi:10.3390/biom11040574
   Web of Science ®Google Scholar
• Betzel B, Cooiman MI, Aarts EO, et al. Clinical follow-up on weight loss, glycemic control, and safety aspects of 24 months of duodenal-jejunal bypass liner implantation. Surg Endosc. 2020;34(1):209–215. doi:10.1007/s00464-019-06752-8
   Web of Science ®Google Scholar
• Laubner K, Riedel N, Fink K, et al. Comparative efficacy and safety of the duodenal-jejunal bypass liner in obese patients with type 2 diabetes mellitus: a case control study. Diabetes Obes Metab. 2018;20(8):1868–1877. doi:10.1111/dom.13300
   Web of Science ®Google Scholar
• Roehlen N, Laubner K, Bettinger D, et al. Duodenal-Jejunal Bypass Liner (DJBL) improves cardiovascular risk biomarkers and predicted 4-year risk of major CV events in patients with type 2 diabetes and metabolic syndrome. Obes Surg. 2020;30(4):1200–1210. doi:10.1007/s11695-019-04324-2
   Web of Science ®Google Scholar
• Glaysher MA, Ward J, Aldhwayan M, et al. The effect of a duodenal-jejunal bypass liner on lipid profile and blood concentrations of long chain polyunsaturated fatty acids. Clin Nutr. 2021;40(4):2343–2354. doi:10.1016/j.clnu.2020.10.026
   Web of Science ®Google Scholar
• Patel SR, Hakim D, Mason J, Hakim N. The duodenal-jejunal bypass sleeve (EndoBarrier Gastrointestinal Liner) for weight loss and treatment of type 2 diabetes. Surg Obes Relat Dis. 2013;9(3):482–484. doi:10.1016/j.soard.2013.01.015
   Web of Science ®Google Scholar
• Abdeen G, le Roux CW. Mechanism underlying the weight loss and complications of Roux-en-Y gastric bypass. review. Obes Surg. 2016;26(2):410–421. doi:10.1007/s11695-015-1945-7
   Web of Science ®Google Scholar
• Aron-Wisnewsky J, Doré J, Clement K. The importance of the gut microbiota after bariatric surgery. Nat Rev Gastroenterol Hepatol. 2012;9(10):590–598. doi:10.1038/nrgastro.2012.161
   Web of Science ®Google Scholar
• Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17(6):819–837. doi:10.1016/j.cmet.2013.04.008
   PubMed Web of Science ®Google Scholar
• Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev. 2008;60(4):470–512. doi:10.1124/pr.108.000604
   PubMed Web of Science ®Google Scholar
• Patriti A, Facchiano E, Sanna A, Gullà N, Donini A. The enteroinsular axis and the recovery from type 2 diabetes after bariatric surgery. Obes Surg. 2004;14(6):840–848. doi:10.1381/0960892041590818
   Web of Science ®Google Scholar
• Shuang J, Zhang Y, Ma L, et al. Relief of diabetes by duodenal-jejunal bypass sleeve implantation in the high-fat diet and streptozotocin-induced diabetic rat model is associated with an increase in GLP-1 levels and the number of GLP-1-positive cells. Exp Ther Med. 2015;10(4):1355–1363. doi:10.3892/etm.2015.2669
   Web of Science ®Google Scholar
• Rohde U, Federspiel CA, Vilmann P, et al. The impact of EndoBarrier gastrointestinal liner in obese patients with normal glucose tolerance and in patients with type 2 diabetes. Diabetes Obes Metab. 2017;19(2):189–199. doi:10.1111/dom.12800
   Web of Science ®Google Scholar
• Koehestanie P, Dogan K, Berends F, et al. Duodenal-jejunal bypass liner implantation provokes rapid weight loss and improved glycemic control, accompanied by elevated fasting ghrelin levels. Endosc Int Open. 2014;2(1):E21–7. doi:10.1055/s-0034-1365222
   Google Scholar
• Vilarrasa N, de Gordejuela AG, Casajoana A, et al. Endobarrier® in grade I obese patients with long-standing type 2 diabetes: role of gastrointestinal hormones in glucose metabolism. Obes Surg. 2017;27(3):569–577. doi:10.1007/s11695-016-2311-0
   Web of Science ®Google Scholar
• Stratmann B, Krepak Y, Schiffer E, et al. Beneficial metabolic effects of duodenal jejunal bypass liner for the treatment of adipose patients with type 2 diabetes mellitus: analysis of responders and non-responders. Horm Metab Res. 2016;48(10):630–637. doi:10.1055/s-0042-115175
   Web of Science ®Google Scholar
• de Moura EG, Lopes GS, Martins BC, et al. Effects of duodenal-jejunal bypass liner (EndoBarrier®) on gastric emptying in obese and type 2 diabetic patients. Obes Surg. 2015;25(9):1618–1625. doi:10.1007/s11695-015-1594-x
   Web of Science ®Google Scholar
• Pournaras DJ, Glicksman C, Vincent RP, et al. The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. Endocrinology. 2012;153(8):3613–3619. doi:10.1210/en.2011-2145
   PubMed Web of Science ®Google Scholar
• Guo A, Li K, Tian HC, et al. FGF19 protects skeletal muscle against obesity-induced muscle atrophy, metabolic derangement and abnormal irisin levels via the AMPK/SIRT-1/PGC-α pathway. J Cell Mol Med. 2021;25(7):3585–3600. doi:10.1111/jcmm.16448
   PubMed Web of Science ®Google Scholar
• Kaválková P, Mráz M, Trachta P, et al. Endocrine effects of duodenal-jejunal exclusion in obese patients with type 2 diabetes mellitus. J Endocrinol. 2016;231(1):11–22. doi:10.1530/JOE-16-0206
   Web of Science ®Google Scholar
• van Nierop FS, de Jonge C, Kulik W, et al. Duodenal-jejunal lining increases postprandial unconjugated bile acid responses and disrupts the bile acid-FXR-FGF19 axis in humans. Metabolism. 2019;93:25–32. doi:10.1016/j.metabol.2018.12.009
   Web of Science ®Google Scholar
• Ley RE, Hamady M, Lozupone C, et al. Evolution of mammals and their gut microbes. Science. 2008;320(5883):1647–1651. doi:10.1126/science.1155725
   PubMed Web of Science ®Google Scholar
• Engen PA, Green SJ, Voigt RM, Forsyth CB, Keshavarzian A. The gastrointestinal microbiome: alcohol effects on the composition of intestinal microbiota. Alcohol Res. 2015;37(2):223–236.
   PubMed Web of Science ®Google Scholar
• Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature. 2006;444(7122):1022–1023. doi:10.1038/4441022a
   PubMed Web of Science ®Google Scholar
• Koulas SG, Stefanou CK, Stefanou SK, et al. Gut microbiota in patients with morbid obesity before and after bariatric surgery: a ten-year review study (2009–2019). Obes Surg. 2021;31(1):317–326. doi:10.1007/s11695-020-05074-2
   PubMed Web of Science ®Google Scholar
• Dang JT, Mocanu V, Park H, et al. Roux-en-Y gastric bypass and sleeve gastrectomy induce substantial and persistent changes in microbial communities and metabolic pathways. Gut Microbes. 2022;14(1):2050636. doi:10.1080/19490976.2022.2050636
   PubMed Web of Science ®Google Scholar
• Li JV, Ashrafian H, Bueter M, et al. Metabolic surgery profoundly influences gut microbial-host metabolic cross-talk. Gut. 2011;60(9):1214–1223. doi:10.1136/gut.2010.234708
   PubMed Web of Science ®Google Scholar
• de Jonge C, Fuentes S, Zoetendal EG, et al. Metabolic improvement in obese patients after duodenal-jejunal exclusion is associated with intestinal microbiota composition changes. Int J Obes. 2019;43(12):2509–2517. doi:10.1038/s41366-019-0336-x
   PubMed Web of Science ®Google Scholar
• Kawai T, Autieri MV, Scalia R. Adipose tissue inflammation and metabolic dysfunction in obesity. Am J Physiol Cell Physiol. 2021;320(3):C375–C391. doi:10.1152/ajpcell.00379.2020
   PubMed Web of Science ®Google Scholar
• Lindegaard KK, Jorgensen NB, Just R, Heegaard PM, Madsbad S. Effects of Roux-en-Y gastric bypass on fasting and postprandial inflammation-related parameters in obese subjects with normal glucose tolerance and in obese subjects with type 2 diabetes. Diabetol Metab Syndr. 2015;7:12. doi:10.1186/s13098-015-0012-9
   Web of Science ®Google Scholar
• Kelly AS, Ryder JR, Marlatt KL, Rudser KD, Jenkins T, Inge TH. Changes in inflammation, oxidative stress and adipokines following bariatric surgery among adolescents with severe obesity. Int J Obes. 2016;40(2):275–280. doi:10.1038/ijo.2015.174
   Web of Science ®Google Scholar
• Agrawal V, Krause KR, Chengelis DL, Zalesin KC, Rocher LL, McCullough PA. Relation between degree of weight loss after bariatric surgery and reduction in albuminuria and C-reactive protein. Surg Obes Relat Dis. 2009;5(1):20–26. doi:10.1016/j.soard.2008.07.011
   PubMed Web of Science ®Google Scholar
• de Jonge C, Rensen SS, D’Agnolo HM, Bouvy ND, Buurman WA, Greve JW. Six months of treatment with the endoscopic duodenal-jejunal bypass liner does not lead to decreased systemic inflammation in obese patients with type 2 diabetes. Obes Surg. 2014;24(2):337–341. doi:10.1007/s11695-013-1154-1
   Web of Science ®Google Scholar
• Betzel B, Drenth JPH, Siersema PD. Adverse events of the duodenal-jejunal bypass liner: a systematic review. Obes Surg. 2018;28(11):3669–3677. doi:10.1007/s11695-018-3441-3
   Web of Science ®Google Scholar
• Maggi U, Formiga A, Lauro R. Hepatic abscess as a complication of duodenal-jejunal bypass sleeve system and review of the literature. Surg Obes Relat Dis. 2016;12(5):e47–e50. doi:10.1016/j.soard.2016.02.018
   Google Scholar
• Riedel N, Laubner K, Lautenbach A, et al. Trends in BMI, glycemic control and obesity-associated comorbidities after explantation of the Duodenal-Jejunal Bypass Liner (DJBL). Obes Surg. 2018;28(8):2187–2196. doi:10.1007/s11695-018-3144-9
   Web of Science ®Google Scholar
• Betzel B, Koehestanie P, Homan J, et al. Changes in glycemic control and body weight after explantation of the duodenal-jejunal bypass liner. Gastrointest Endosc. 2017;85(2):409–415. doi:10.1016/j.gie.2016.07.027
   Web of Science ®Google Scholar
• Leventi E, Günthert SJ, Stier C, Staikov P, Stein J, Farrag K. Is early reimplantation of the duodenal-jejunal bypass liner viable? Obes Surg. 2019;29(5):1690–1693. doi:10.1007/s11695-019-03758-y
   Web of Science ®Google Scholar
• Sartoretto A, Marinos G, Sui Z. Concurrent placements of a duodenal-jejunal bypass liner and an intragastric balloon among severely obese patients: a case series. ACG Case Rep J. 2019;6(6):e00101. doi:10.14309/crj.0000000000000101
   Web of Science ®Google Scholar
• Ghoz H, Jaruvongvanich V, Matar R, et al. A preclinical animal study of combined intragastric balloon and duodenal-jejunal bypass liner for obesity and metabolic disease. Clin Transl Gastroenterol. 2020;11(9):e00234. doi:10.14309/ctg.0000000000000234
   Web of Science ®Google Scholar